Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy Rating
BMO Capital Markets upgraded Maplight Therapeutics (NASDAQ:MPLT) to a "strong-buy" rating. This upgrade follows several other analysts' reports, resulting in the company currently holding an average "Buy" rating and a price target of $40.09. The article also details recent insider selling activity and institutional …